Hepatocellular Carcinoma: Portuguese Data in Chronic Hepatitis B Patients on Antiviral Therapy and Treatment Results With Sorafenib
Author:
Open Access
- 1 September 2016
- journal article
- Published by S. Karger AG in GE - Portuguese Journal of Gastroenterology
- Vol. 23 (5) , 231-232
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinomaLiver International, 2015
- Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenibJournal of Hepatology, 2014
- Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinomaWorld Journal of Hepatology, 2014
- Sorafenib in Advanced Hepatocellular CarcinomaAmerican Journal of Clinical Oncology, 2013
- Epidemiology of Hepatocellular CarcinomaJournal of Clinical Gastroenterology, 2013
- Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infectionWorld Journal of Gastroenterology, 2013
- Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinomaHepatology, 2012
- Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with SorafenibThe Oncologist, 2010
- Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005Journal of Clinical Oncology, 2009
- Rising costs and hospital admissions for hepatocellular carcinoma in Portugal (1993-2005)World Journal of Gastroenterology, 2007